On March 5, 2024 Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, reported the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic (Press release, Bonum Therapeutics, MAR 5, 2024, View Source [SID1234640836]). Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Abstract Title: "A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells."

Presenter: Justin Killebrew, PhD, Senior Director, Immuno-Oncology Discovery at Bonum Therapeutics

Abstract Number: 4062

Date/Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT

Session Title: Immune Modulation with Cytokines

The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.

John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, "We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR (Free AACR Whitepaper)."

The poster will be available on the Bonum website on the day of the presentation.

Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.

Bonum’s core platform enables the engineering and development of a broad array of important medicines. Initially, Bonum is applying the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, it is seeking partners for applications of its technology in other disease areas where the partner brings expertise in a specific biology and can help guide choices to create new therapies and reach patients as quickly as possible.

On March 5, 2024 AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, reported that it will present an abstract in a poster session at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 5-10, 2024, in San Diego, California (Press release, AffyImmune Therapeutics, MAR 5, 2024, View Source [SID1234640835]). Presented findings will highlight research applying the affinity-tuned, trackable, ICAM-1 targeting CAR T cell therapy AIC100 to additional solid tumor types where there is significant unmet medical need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Poster Title: AIC100 CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer (CC).

Date and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM

Presenting Author: Alyssa Birt, AffyImmune Therapeutics

Session Category: Immunology

Session Title: Adoptive Cell Therapies 3: CAR-T Cells

Location: Poster Section 2, Poster Board Number: 16

Published Abstract Number: 4007

On March 5, 2024 Tubulis reported that two abstracts with comprehensive preclinical data on their next-generation antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040, have been accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024 in San Diego (Press release, Tubulis, MAR 5, 2024, View Source [SID1234640834]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tubulis is building a pipeline of uniquely matched ADCs, tailored to respective disease biology by leveraging the company’s proprietary suite of platform technologies to combine the right targeting molecule, conjugation chemistry and payload. TUB-030 is directed against the tumor-associated antigen 5T4 which addresses a wide range of solid tumor indications. TUB-040 targets Napi2b, a well-characterized target in ovarian and lung cancer. Both ADC candidates are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

"Our novel technologies allow us to push the boundaries of ADC design to fully leverage the biology of well-understood therapeutic targets as well as unlock less-validated ones to create treatments that deliver meaningful patient benefit. The results we will present at the AACR (Free AACR Whitepaper) Annual Meeting will highlight the preclinical differentiation of our two lead candidates, TUB-030 and TUB-040. We believe that these two ADC candidates hold great potential to effectively enable durable responses and prolong overall survival in patients with a broad range of solid tumors while maintaining a significant safety and tolerability profile," said Jonas Helma-Smets, Chief Scientific Officer of Tubulis. "We look forward to further investigating the impact these two candidates can make in the clinic."

Details of the poster presentations:

TUB-030 Poster Information

Title: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
Presenter: Jonas Helma-Smets, CSO of Tubulis
Session Category and Title: Immunology – Antibody-Drug Conjugates
Session Date and Time: Monday, Apr 8, 2024, 1:30 PM – 5:00 PM PT
Location: Poster Section 2
Abstract Number: 2623

The poster will highlight the pre-clinical proof-of-concept data for TUB-030, an ADC that targets the oncofetal 5T4 antigen. 5T4 is a tumor-associated protein that is overexpressed in various types of cancers, including bladder, lung, breast, stomach, esophagus, head and neck, colon, and ovarian cancer. Tubulis’ ADC candidate differs from previous ADCs targeting 5T4 by implementing several layers of differentiation in terms of antibody, payload and conjugation technology. It combines the company’s proprietary P5 conjugation technology with its Tubutecan topoisomerase-I payload platform, resulting in a homogenous DAR (drug-antibody-ratio) of 8. TUB-030 has shown strong cytotoxicity towards cancer cells from different tumor indications with a broad range of 5T4 expression levels. Pharmacokinetic analysis further demonstrated the highly stable profile of TUB-030, enabling the efficient delivery of the payload to the tumor.

TUB-040 Poster Information

Title: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans
Presenter: Jonas Helma-Smets, CSO of Tubulis
Session Category and Title: Immunology – Antibody-Drug Conjugates
Session Date and Time: Monday, Apr 8, 2024, 1:30 PM – 5:00 PM PT
Location: Poster Section 2
Published Abstract Number: 2622

The poster will provide a detailed overview of the preclinical proof-of-concept for TUB-040. The ADC candidate is directed against Napi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma. Its IgG1 antibody targeting Napi2b is connected to its payload, the Topoisomerase I inhibitor Exatecan through a cleavable linker system. The company’s P5 conjugation technology was used to build TUB-040 with a homogenous DAR of 8. TUB-040 induces DNA damage and cell death, without causing unspecific uptake and cytotoxicity in healthy, target-negative cells. Moreover, Pharmacokinetic analysis showed that TUB-040 is highly stable, thus efficiently delivering its payload to the tumor while reducing offsite toxicities.

The full abstracts will be published on March 22, 2024, in an online-only proceedings supplement to the AACR (Free AACR Whitepaper) journal, Cancer Research. The company will issue a press release detailing the full preclinical data following the presentation at AACR (Free AACR Whitepaper).

On March 5, 2024 EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, reported the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, California between April 5-10, 2024 (Press release, EpimAb Biotherapeutics, MAR 5, 2024, View Source [SID1234640833]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This presentation will highlight the preclinical results for EMB-07, a novel ROR1 targeting TCE designed with an optimized efficacy, safety and pharmacokinetic profile. Furthermore, the presentation will discuss the TCE’s differentiated in vitro potency relative to benchmark molecules constructed using different modalities. The presentation details are as follows:

Title: Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
Session Date: April 8, 2024
Session Time: 9:00AM – 12:30PM local time
Presentation number: LB126 (poster section 52, number 14)

"With EMB-07 EpimAb is applying a unique and proprietary approach to target ROR1, a protein expressed on the surface of a multitude of solid and liquid tumor cells," Dr. Chengbin Wu, Founder and CEO of EpimAb commented. "We are very excited to share the preliminary preclinical findings for this bispecific at the AACR (Free AACR Whitepaper) Annual Meeting, and look forward to further unlocking the potential of our T-cell engager and bispecific antibody platforms to target diseases with unmet need and help patients around the world."

About EMB-07
EMB-07 is a novel ROR1×CD3 T-cell engaging bispecific antibody developed based on EpimAb’s proprietary bispecific antibody platforms. This molecule was carefully designed for an optimized efficacy and safety profile, as demonstrated by only modest levels of cytokine release in preclinical studies. EMB-07 is currently being evaluated in a Phase I trial in solid tumors and lymphomas (NCT05607498; CTR20230350).

On March 5, 2024 Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, reported receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET (Press release, Dragonfly Therapeutics, MAR 5, 2024, View Source [SID1234640832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie’s budigalimab (ABBV-181), in solid tumors.

"We are delighted that AbbVie has advanced ABBV-303 into the clinic," said Bill Haney, CEO and Dragonfly co-founder. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."

Additional information about the M24-122 Phase 1 trial, can be found at: View Source (ClinicalTrials.gov Identifier: NCT06158958).